ArticleCell communication and signaling : CCS2026
Activation of c-Myc confers resistance to venetoclax via inhibition of Bim in t(8;21)-positive acute myeloid leukemia.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
background and purposeVenetoclax (VEN), a selective BCL-2 inhibitor, has improved outcomes in acute myeloid leukemia (AML). However, patients carrying the t(8;21)(q22;q22) translocation often show limited sensitivity to VEN-based therapy. This study aimed to elucidate the molecular mechanism of VEN resistance and explore rational combination strategies. EXPERIMENTAL APPROACH: Molecular and functional analyses were performed in t(8;21) AML models to examine the role of c-Myc activation in VEN response. Pharmacologic inhibition, genetic knockdown, and xenograft studies were used to assess the effects of c-Myc and its downstream effector Bim. The efficacy of VEN combined with homoharringtonine (HHT) was further evaluated. KEY
resultsVEN induced c-Myc expression in a dose-dependent manner, which was not suppressed by azacitidine. Inhibition or knockdown of c-Myc enhanced VEN-induced apoptosis. Mechanistically, c-Myc repressed the pro-apoptotic BH3-only protein Bim, reducing mitochondrial priming and conferring VEN resistance. HHT downregulated c-Myc and restored Bim expression, leading to synergistic anti-leukemic activity with VEN in vitro and in vivo. CONCLUSIONS AND IMPLICATIONS: c-Myc activation is a key driver of VEN resistance in t(8;21) AML. HHT acts as a mechanistically complementary agent, restoring VEN sensitivity. These results provide a preclinical rationale for clinical evaluation of VEN-HHT combination therapy in genetically defined AML subsets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.